Copyright
©The Author(s) 2019.
World J Gastroenterol. Jul 21, 2019; 25(27): 3607-3618
Published online Jul 21, 2019. doi: 10.3748/wjg.v25.i27.3607
Published online Jul 21, 2019. doi: 10.3748/wjg.v25.i27.3607
Table 1 Patients’ baseline characteristics
| Variable | Values |
| Age, yr (± SD) | 63 ± 10 |
| Male gender, n (%) | 265 (81.3) |
| Non-cirrhotic liver, n (%) | 41 (12.5) |
| Child Pugh A/B/C, n (%) | 137 (42)/98 (30)/92 (28) |
| Etiology of liver disease, n (%) | |
| Hepatitis C virus | 99 (30.3) |
| Alcohol | 77 (23.5) |
| NASH | 35 (10.7) |
| Cryptogenic | 37 (11.3) |
| Hepatitis B virus | 22 (6.7) |
| Cholestatic1 | 4 (1.2) |
| Autoimmune | - |
| Hemochromatosis | 6 (1.8) |
| Miscellaneous | 36 (11.0) |
| Comorbidities, n (%) | 141 (43.1) |
| Diabetes mellitus, n (%) | 84 (25.7) |
| Ascites, n (%) | |
| Mild | 76 (23.3) |
| Moderate-severe | 77 (23.5) |
| Encephalopathy, n (%) | |
| Grade I-II | 78 (23.8) |
| Grade III-IV | 6 (1.8) |
| CSPH, n (%) | 212 (64.8) |
| ECOG 0-2, n (%) | 262 (80.1) |
Table 2 Stratified analysis comparing transarterial chemoembolization treatment in barcelona clinic liver cancer stage B
| Variable | BCLC stage B overall (n = 135) | BCLC stage B with TACE (n = 77) | BCLC stage B without TACE (n = 58) | P value |
| Age, yr (± SD) | 65 ± 10 | 65 ± 8 | 65 ± 11 | 0.86 |
| Male gender, n (%) | 111 (82.2) | 68 (88.3) | 43 (74.1) | 0.03 |
| Non-cirrhotic liver, n (%) | 23 (17.0) | 7 (9.1) | 16 (27.6) | 0.006 |
| Etiology, n (%) | 0.11 | |||
| HCV | 42 (31.1) | 25 (32.5) | 17 (29.3) | |
| HBV | 8 (5.9) | 5 (6.5) | 3 (5.2) | |
| Alcohol | 29 (21.5) | 21 (27.3) | 8 (13.8) | |
| Etiology, nNASH | 14 (10.4) | 6 (7.8) | 8 (13.8) | |
| Etiology, nOthers | 42 (31.1) | 20 (25.9) | 22 (37.9) | |
| Child Pugh A/B, n (%) | 88 (65.2)/47 (34.8) | 48 (62.3)/29 (37.7) | 40 (69.0)/18 (31.0) | 0.42 |
| CSPH1, n (%) | 67 (49.6) | 45 (58.4) | 22 (37.9) | 0.018 |
| Median nº HCC nodules (IQR) | 2 (2-3) | 2 (1-3) | 2 (1-4) | 0.39 |
| Median largest HCC diameter, mm, (IQR) | 65 (43-100) | 60 (43-88) | 69.5 (45-114.5) | 0.11 |
| Bilobar involvement, n (%) | 53 (39.3) | 30 (39.0) | 23 (39.7) | 0.72 |
| Diffuse HCC pattern, n (%) | 5 (3.7) | 2 (2.6) | 3 (5.2) | 0.72 |
| Median AFP, ng/mL (IQR) | 26.7 (4.7-248.5) | 27.5 (5.1-202.85) | 24.4 (4.3-285) | 0.91 |
| AFP > 200 ng/mL, n (%) | 36 (27.3) | 19 (25.0) | 17 (30.4) | 0.49 |
| AFP > 400 ng/mL, n (%) | 30 (22.7) | 17 (22.4) | 13 (23.2) | 0.91 |
| AFP > 1000 ng/mL, n (%) | 18 (13.6) | 11 (14.5) | 7 (12.5) | 0.74 |
| Vascular invasion, n (%) | - | |||
| Extrahepatic disease, n (%) | - |
Table 3 Characteristic of patients treated with sorafenib
| Variable | Overall (n = 82) | BCLC stage B (n = 36) | BCLC stage C (n = 36) | BCLC stage D (n = 10) | P value |
| Age, yr (± SD) | 63 ± 9 | 63 ± 8 | 62 ± 10 | 63 ± 8 | 0.86 |
| Male gender, n (%) | 68 (82.9) | 29 (80.6) | 31 (86.1) | 8 (80.0) | 0.88 |
| Non-cirrhotic liver, n (%) | 9 (11.0) | 3 (8.3) | 5 (13.9) | 1 (10.0) | 0.78 |
| Etiology, n (%) | 0.11 | ||||
| HCV | 28 (34.1) | 16 (44.4) | 11 (30.6) | 1 (10.0) | |
| HBV | 4 (4.9) | 2 (5.6) | 1 (2.8) | 1 (10.0) | |
| Alcohol | 18 (21.9) | 9 (25.0) | 8 (22.2) | 1 (10.0) | |
| NASH | 10 (12.2) | 4 (11.1) | 4 (11.1) | 2 (20.0) | |
| Others | 22 (26.8) | 5 (13.9) | 12 (33.3) | 5 (50.0) | |
| Child Pugh A/B/C, n (%) | 48 (58)/30 (37)/4 (5) | 25 (69)/11 (31)/- | 21 (58)/15 (42)/- | 2 (20)/4 (40)/4 (40) | |
| CSPH1, n (%) | 45 (54.9) | 21 (58.3) | 18 (50.0) | 6 (60.0) | 0.66 |
| Median nº HCC nodules (IQR)2 | 2 (1-4) | 2 (2-4) | 2 (1-4) | 1.5 (1-2) | 0.25 |
| Median largest HCC diameter, mm, (IQR)2 | 70 (47-100) | 65 (46-90) | 87 (48.5-130) | 57.5 (39-121) | 0.56 |
| Bilobar involvement, n (%) | 30 (37.0) | 10 (27.8) | 18 (50.0) | 3 (30.0) | 0.33 |
| Diffuse HCC pattern, n (%) | 6 (7.4) | 2 (5.6) | 3 (8.3) | 1 (10.0) | 0.35 |
| Median AFP, ng/mL (IQR) | 103 (7.0-1069) | 30 (7.2-739) | 150 (6.3-1210) | 649 (16-2198) | 0.26 |
| AFP > 200 ng/mL, n (%) | 35 (43.7) | 12 (34.3) | 16 (45.7) | 7 (70) | 0.13 |
| AFP > 400 ng/mL, n (%) | 30 (37.5) | 10 (28.6) | 13 (37.1) | 7 (70) | 0.06 |
| AFP > 1000 ng/mL, n (%) | 21 (25.9) | 5 (14.3) | 12 (33.3) | 4 (40) | 0.13 |
| Vascular invasion, n (%) | 27 (33.3) | - | 25 (69.4) | 3 (30.0) | < 0.0001 |
| Extrahepatic disease, n (%) | 19 (23.5) | - | 18 (50.0) | 1 (10.0) | < 0.0001 |
- Citation: Piñero F, Marciano S, Fernández N, Silva J, Anders M, Zerega A, Ridruejo E, Romero G, Ameigeiras B, D’Amico C, Gaite L, Bermúdez C, Reggiardo V, Colombato L, Gadano A, Silva M. Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis. World J Gastroenterol 2019; 25(27): 3607-3618
- URL: https://www.wjgnet.com/1007-9327/full/v25/i27/3607.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i27.3607